Q4 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$126M-3.4% YoY

Gross Profit

$115M91.3% margin

Operating Income

$50M39.3% margin

Net Income

$48M37.9% margin

EPS (Diluted)

$0.30

QoQ Revenue Growth

-3.7%

Cash Flow

Operating Cash Flow

$28M

Free Cash Flow

$25M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$403M

Total Liabilities

$496M

Stockholders' Equity

-$93M

Cash & Equivalents

$177M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$126M	$131M	-3.4%
Gross Profit	$115M	$109M	+5.5%
Operating Income	$50M	$6M	+727.2%
Net Income	$48M	-$15M	+408.9%

Revenue Segments

Collaborative Arrangements

$106M81%

Active Pharmaceutical Ingredient

$21M16%

Collaborative Arrangement Promotion Agreement

$2M2%

Collaborative Arrangement Co Promotion Agreement

$1M1%

Collaborative Arrangement Other Agreements

$229,0000%

Geographic Segments

$102M98%

North America

$603,0001%

Canada And Mexico

$600,0001%

Europe And Other

$510,0000%

Europe

$500,0000%

China Hong Kong And Macau

$227,0000%

$88,0000%